Journal
INTERNATIONAL JOURNAL OF CLINICAL PRACTICE
Volume 65, Issue 4, Pages 397-407Publisher
WILEY-HINDAWI
DOI: 10.1111/j.1742-1241.2011.02656.x
Keywords
-
Funding
- Novo Nordisk A/S, Bagsvaerd, Denmark
- Novo Nordisk
- Merck Co.
- Novartis Pharmaceuticals
- Eli Lilly Co.
- Novartis Pharmaceuticals Corporation
- Novo Nordisk A/S
- Pfizer Inc.
- sanofi-aventis
- Bayer Vital Pharma
- Menarini/Berlin-Chemie
- Merck Sharp Dohme
- Novartis Pharma
- Animas Corporation
- Becton Dickinson
- CPEX Pharmaceuticals
- Dexcom
- GlaxoSmithKline
- Medtronic MiniMed
- Merck
- Novo Nordisk Inc.
- Resmed
- Lifescan
- Eli Lilly
- Novartis
- Merck Sharp Dohme Ltd.
Ask authors/readers for more resources
P>Aim: The aim of this study was to compare the efficacy and safety of once-daily human glucagon-like peptide-1 analogue liraglutide with dipeptidyl peptidase-4 inhibitor sitagliptin, each added to metformin, over 52 weeks in individuals with type 2 diabetes. Methods: In an open-label, parallel-group trial, metformin-treated participants were randomised to liraglutide 1.2 mg/day (n = 225), liraglutide 1.8 mg/day (n = 221) or sitagliptin 100 mg/day (n = 219) for 26 weeks (main phase). Participants continued the same treatment in a 26-week extension. Results: Liraglutide (1.2 or 1.8 mg) was superior to sitagliptin for reducing HbA(1c) from baseline (8.4-8.5%) to 52 weeks: -1.29% and -1.51% vs. -0.88% respectively. Estimated mean treatment differences between liraglutide and sitagliptin were as follows: -0.40% (95% confidence interval -0.59 to -0.22) for 1.2 mg and -0.63% (-0.81 to -0.44) for 1.8 mg (both p < 0.0001). Weight loss was greater with liraglutide 1.2 mg (-2.78 kg) and 1.8 mg (-3.68 kg) than sitagliptin (-1.16 kg) (both p < 0.0001). Diabetes Treatment Satisfaction Questionnaire scores increased significantly more with liraglutide 1.8 mg than with sitagliptin (p = 0.03). Proportions of participants reporting adverse events were generally comparable; minor hypoglycaemia was 8.1%, 8.3% and 6.4% for liraglutide 1.2 mg, 1.8 mg and sitagliptin respectively. Gastrointestinal side effects, mainly nausea, initially occurred more frequently with liraglutide, but declined after several weeks. Conclusion: Liraglutide provides greater sustained glycaemic control and body weight reduction over 52 weeks. Treatment satisfaction was significantly greater with 1.8 mg liraglutide, similar to 26-week results. The safety profiles of liraglutide and sitagliptin are consistent with previous reports.
Authors
I am an author on this paper
Click your name to claim this paper and add it to your profile.
Reviews
Recommended
No Data Available